Evidence map›Paper›PMID 31947704›Full record

ReviewBiomolecules2020

A Review of the Structure-Activity Relationship of Natural and Synthetic Antimetastatic Compounds.

Su Ki Liew, Sharan Malagobadan, Norhafiza M Arshad, Noor Hasima Nagoor

Abstract readReview
In one paragraph

Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Molecules (Basel, Switzerland) · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Anti-cancer agents in medicinal chemistry · 2025
    Article
  11. Article
  12. Article
  13. Selagibenzophenone B and Its Derivatives:ACS bio & med chem Au · 2024
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Toward Understanding the Anticancer Activity of the Phytocompounds fromAdvances and applications in bioinformatics and chemistry : AABC · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Su Ki LiewInstitute of Biological Science (Genetics and Molecular Biology), Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.
Sharan MalagobadanInstitute of Biological Science (Genetics and Molecular Biology), Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.
Norhafiza M ArshadCentre for Research in Biotechnology for Agriculture (CEBAR), University of Malaya, Kuala Lumpur 50603, Malaysia.
Noor Hasima NagoorInstitute of Biological Science (Genetics and Molecular Biology), Faculty of Science, University of Malaya, Kuala Lumpur 50603, Malaysia.

Funding

Centre for Research in Biotechnology for Agriculture (CEBAR) Grant RU006-2017
6 · The paper itself

Abstract

There are innumerable anticancer compounds derived from either natural or synthetic origins. Many of these compounds have been further developed through structural modifications to not only inhibit cancer cell growth but also to exert an antimetastatic effect. This is achieved by attaching different substituents to generate different structure-activity relationships. This review highlights the effectiveness of different functional groups known to have antimigration and antiproliferation activities, such as fluoro, methoxy, methyl, amino, hydroxy, nitro, bromo, chloro, methylamino, ethoxy, carbonyl, iodo, and trifluoromethyl groups. Additionally, the positioning of these functional groups plays an important role in their anticancer activities, which was evident in one of our studies comparing analogues of a natural compound. Thus, this review suggests future recommendations for the design and development of improved anticancer drugs with higher efficacy.

Indexed as

AnimalsAntineoplastic AgentsBiological ProductsCell MovementCell ProliferationHumansNeoplasm MetastasisNeoplasmsStructure-Activity RelationshipAntineoplastic AgentsBiological Productsantimetastasisbiotechnologystructure-activity relationshipssubstituentsynthesis

Identifiers

PMID31947704
PMCPMC7022821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.